Abstract

Circulating apolipoprotein B-containing lipoproteins, notably the low-density lipoproteins, enter the inner layer of the arterial wall, the intima, where a fraction of them is retained and modified by proteases, lipases, and oxidizing agents and enzymes. The modified lipoproteins and various modification products, such as fatty acids, ceramides, lysophospholipids, and oxidized lipids induce inflammatory reactions in the macrophages and the covering endothelial cells, initiating an increased leukocyte diapedesis. Lipolysis of the lipoproteins also induces the formation of cholesterol crystals with strong proinflammatory properties. Modified and aggregated lipoproteins, cholesterol crystals, and lipoproteins isolated from human atherosclerotic lesions, all can activate macrophages and thereby induce the secretion of proinflammatory cytokines, chemokines, and enzymes. The extent of lipoprotein retention, modification, and aggregation have been shown to depend largely on differences in the composition of the circulating lipoprotein particles. These properties can be modified by pharmacological means, and thereby provide opportunities for clinical interventions regarding the prevention and treatment of atherosclerotic vascular diseases.

Highlights

  • Atherosclerosis develops in the inner layer of the arterial wall, the intima

  • In vascular smooth muscle cells (SMCs), foam cell formation due to uptake of native and modified VLDL was shown to depend on the activity of lipoprotein lipase [90], while the LDL receptor-related protein 1 plays a role in the uptake of aggregated LDL [91]

  • Modified lipoproteins are the main drivers of atherogenic inflammation of the arterial wall (Figure 3)

Read more

Summary

Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis

Reviewed by: Mark Borja, California State University, United States Robert Kiss, McGill University, Canada. Circulating apolipoprotein B-containing lipoproteins, notably the low-density lipoproteins, enter the inner layer of the arterial wall, the intima, where a fraction of them is retained and modified by proteases, lipases, and oxidizing agents and enzymes. Cholesterol crystals, and lipoproteins isolated from human atherosclerotic lesions, all can activate macrophages and thereby induce the secretion of proinflammatory cytokines, chemokines, and enzymes. The extent of lipoprotein retention, modification, and aggregation have been shown to depend largely on differences in the composition of the circulating lipoprotein particles. These properties can be modified by pharmacological means, and thereby provide opportunities for clinical interventions regarding the prevention and treatment of atherosclerotic vascular diseases

INTRODUCTION
Lipoprotein Modification
Foam Cell Formation
INFLAMMATION VIA INNATE IMMUNE
Vortexed and Acetylated Lipoproteins
Circulating Modified Lipoproteins
Function in atherogenesis
Macrophages Monocytes ECs ECs ECs Macrophages
Monocytes VSMCs
Phospholipolytically Modified Lipoproteins
Oxidized Lipoproteins
Neutrophil Extracellular Traps
ADAPTIVE IMMUNE SYSTEM RESPONSE AND AUTOIMMUNE COMPONENT
LIPID MEDIATORS IN MODIFIED LIPOPROTEINS IMPAIR RESOLUTION
DYSFUNCTIONAL HDL
INFLAMMATION INDUCED BY MODIFIED
Findings
CONCLUDING REMARKS AND FUTURE
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call